FDA approves Janssen's gemcitabine system for bladder cancer
The agency cleared Inlexzo for a specific group of bladder cancer patients who did not respond to standard BCG therapy.
The Food and Drug Administration approved gemcitabine intravesical system, sold as Inlexzo and made by Janssen Biotech, Inc., on September 9, 2025. The approval covers adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer that includes carcinoma in situ, with or without accompanying papillary tumors.1
This marks a treatment option for patients whose non-muscle invasive bladder cancer has stopped responding to BCG, a bacterial therapy long used as a standard approach for this disease stage. Carcinoma in situ refers to a flat, high-grade form of bladder cancer confined to the inner lining, and its presence alongside papillary tumors or on its own defines the patient population eligible for this new therapy under the approval.
No additional details on dosing, administration schedule, trial data, or company statements were included in the FDA's approval notice as provided.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.